● Recruiting

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer(NSCLC) · Sponsor: Pingping Song

PhasePhase 2

Planned participants26

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).

This description comes directly from the study's public registry record.

Talk to the study team

Pingping Song · 18663776711 · SPP128@126.com

Guodong Zhang · 15701206264 · zzkzgd@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shandong Cancer Hospital and Institute

Jinan, Shandong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05765877